Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


International News In Brief

This article was originally published in The Gray Sheet

Executive Summary

MHRA leadership: Alasdair Breckenridge is appointed chair-designate of UK's Medicines and Healthcare products Regulatory Agency Nov. 28. The pharmacology professor has served for the Committee on the Safety of Medicines since 1984 and as chairman since 1999. He has an "excellent understanding of the regulation of pharmaceutical products," DoH says. Breckenridge still must acquire a similar knowledge of medical equipment regulation, however, as consolidation of the Medical Devices Agency and the Medicines Control Agency is expected to retain MDA's focus on devices (1"The Gray Sheet" Sept. 30, 2002, p. 15). One of Breckenridge's first tasks will be to recruit MHRA's first chief executive and a new board...

You may also be interested in...

Germany Lures Hospitals To DRGs Despite Modest Implementation Resources

Legislation under consideration in Germany will exclude hospitals joining an optional DRG establishment period in 2003 from a freeze on health care funds, providing hesitant centers an incentive to join the system, according to device association BVMed

MHRA Will Pay Equal Attention To Devices and Drugs, UK Health Chief Vows

Consolidaton of the Medical Devices Agency and the Medicines Control Agency will retain MDA's focus on the device industry, UK Health Minister Lord Philip Hunt said Sept. 19

Alaris Medical Systems

U.K. Medical Devices Agency warns of possible over-infusion from Alaris' P1000, P2000, P3000 lines of syringe pumps due to obsolete software related to volume limit and bolus features, as well as a typographical error in product labeling. Clinicians are advised to contact Alaris for upgraded software, and to attach an interim label correcting the error. "The most serious effect of this error, if not detected by the user, is over-infusion due to the pump running at the Keep Vein Open rate instead of automatically stopping once the volume limit is reached," MDA states in Oct. 23 notice

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts